In vivo enhancement in bioavailability of atazanavir in the presence of proton-pump inhibitors using mesoporous materials

ChemMedChem

Volumn 7, Issue 1, 2012, Pages 43-48

  Xia, Xin ^b,c   Zhou, Chunfang ^b   Ballell, Lluís ^d   Garcia Bennett, Alfonso E ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b NANOLOGICA AB   (Sweden)

^c STOCKHOLM UNIVERSITY   (Sweden)

^d GLAXOSMITHKLINE   (Spain)

Author keywords

Drug delivery; Human immunodeficiency virus (HIV); Mesoporous silica; Proton pump inhibitors; Solubility

Indexed keywords

ATAZANAVIR; DRUG CARRIER; NANOMATERIAL; OMEPRAZOLE; PROTON PUMP INHIBITOR; SILICON DIOXIDE;

ARTICLE; CRYSTALLIZATION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RELEASE; DRUG SOLUBILITY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VIVO STUDY; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RAT; SCANNING ELECTRON MICROSCOPY; THERMOGRAVIMETRY; TRANSMISSION ELECTRON MICROSCOPY;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANIMALS; ANTI-HIV AGENTS; DRUG CARRIERS; HUMANS; OLIGOPEPTIDES; POROSITY; PROTON PUMP INHIBITORS; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; SILICON DIOXIDE; SOLUBILITY;

EID: 84555188732     PISSN: 18607179     EISSN: 18607187     Source Type: Journal    
DOI: 10.1002/cmdc.201100500     Document Type: Article

References (37)

1. Part 1: Oral Delivery of Poorly Soluble Drugs, M. Hite, S. Turner, C. Federici, Pharm. Manuf. Pack. Sourc. (PMPS) 2003, summer; available here: (Last accessed: November 10, 2011).
2. H. Hou, R. A. Siegel, J. Pharm. Sci. 2006, 95, 896-905.
3. R. G. Strickley, Pharm. Res. 2004, 21, 201-230.
4. R. G. Strickley, R. Oliyai in Solvent Systems and their Selection in Pharmaceutics and Biopharmaceutics, (Eds.: P. Augustijns, M.E. Brewster), AAPS Press and Springer, New York, 2007, pp.257-308.
5. L. Appel, W. Babcock, D. T. Friesen, R. J. Ray, S. Shamblin, R. Shanker, D. Smithey, (Pfizer Products Inc., Groton, CT, USA), Int. Pat. Appl. WO 2006/024944A2, 2006.
6. M. E. Matteucci, B. K. Brettmann, T. L. Rogers, E. J. Elder, R. O. Williams III, K. P. Johnston, Mol. Pharm. 2007, 4, 782-793.
7. K. A. Overhoff, J. T. McConville, W. Yang, K. P. Johnston, J. I. Peters, R. O. Williams III, Pharm. Res. 2008, 25, 167-175.
8. A. T. Serajuddin, J. Pharm. Sci. 1999, 88, 1058-1066.
9. C. Leuner, J. Dressman, Eur. J. Pharm. Biopharm. 2000, 50, 47-60.
10. A. R. Mohammed, N. Weston, A. G. A. Coombes, M. Fitzgerald, Y. Perrie, Int. J. Pharm. 2004, 285, 23-34.
11. M. T. Morgan, Y. Nakanishi, D. J. Kroll, A. P. Griset, M. A. Carnahan, M. Wathier, N. H. Oberlies, G. Manikumar, M. C. Wani, M. W. Grinstaff, Cancer Res. 2006, 66, 11913-11921.
12. V. Swali, N. J. Wells, G. J. Langley, M. Bradley, J. Org. Chem. 1997, 62, 4902-4903.
13. J. Salonen, L. Laitinen, A. M. Kaukonen, J. Tuura, M. Björkqvist, T. Heikkilä, K. Vähä-Heikkilä, J. Hir-vonen, V. Lehto, J. Controlled Release 2005, 108, 362-374.
14. A. M. Kaukonen, L. Laitinen, J. Salonen, J. Tuura, T. Heikkilä, T. Limnell, J. Hirvonen, V. Lehto, Eur. J. Pharm. Biopharm. 2007, 66, 348-356.
15. R. Mellaerts, C. A. Aerts, J. VanHumbeeck, P. Augustijns, G. VandenMooter, J. A. Martens, Chem. Commun. 2007, 1375-1377.
16. M. Vallet-Regí, F. Balas, D. Arcos, Angew. Chem. 2007, 119, 7692-7703; Angew. Chem. Int. Ed. 2007, 46, 7548-7558.
17. J. Lu, M. Liong, Z. Li, J. I. Zink, F. Tamanoi, Small 2010, 6, 1794-1805.
18. R. Mellaerts, R. Mols, P. Kayaert, P. Annaert, J. VanHumbeeck, G. VandenMooter, J. A. Martens, P. Augustijns, Int. J. Pharm. 2008, 357, 169-179.
19. M. VanSpeybroeck, R. Mellaerts, R. Mols, T. D. Thi, J. A. Martens, J. VanHumbeeck, Eur. J. Pharm. Sci. 2010, 41, 623-630.
20. R. Atluri, N. Hedin, A. E. Garcia-Bennett, J. Am. Chem. Soc. 2009, 131, 3189-3191.
21. A. E. Garcia-Bennett, S. Che, K. Miyasaka, O. Terasaki, Chem. Mater. 2004, 16, 3597-3605.
22. R. P. Hodgkins, A. E. Garcia-Bennett, P. A. Wright, Micro. Meso. Mater. 2005, 79, 241-252.
23. A. Sosnik, D. A. Chiappetta, A. M. Carcaboso, J. Controlled Release 2009, 138, 2-15.
24. C. A. Lipinski, F. Lombardo, B. W. Dominy, P. J. Feeney, Adv. Drug Delivery Rev. 2001, 46, 3-26.
25. Prescribing information for atazanavir sulfate (Reyataz) capsules. Bristol-Myers Squibb (Princeton, NJ, USA), July 2004.
26. M. Strømme, U. Brohede, R. Atluri, A. E. Garcia-Bennett, Wiley Interdiscip. Rev.: Nanomed. Nanotechnol. 2009, 1, 140-148.
27. R. Prasad, S. Lele, Philos. Mag. Lett. 1994, 70, 357-361.
28. G. T. Rengarajan, D. Enke, M. Steinhart, M. Berner, J. Mater. Chem. 2008, 18, 2537-2539.
29. C. L. Jackson, G. B. McKenna, Chem. Mater. 1996, 8, 2128-2137.
30. M. Alcoutlabi, G. B. McKenna, J. Phys. Condens. Matter 2005, 17, R461-R524.
31. The structure and properties of atazanavir are summarized here: (Last accessed: November 10, 2011).
32. S. Kim, B. T. Lotz, J. Z. Gougoutas, M. Davidovich, S. K. Srivastava, (Bristol-Myers Squibb Co.), US Pat. Appl. US2011/0124689A1, 2011.
33. S. Brunauer, P. H. Emmett, E. Teller, J. Am. Chem. Soc. 1938, 60, 309-319.
34. P. Tarazona, Phys. Rev. A 1985, 31, 2672-2679.
35. P. Tarazona, U. MariniBettoloMarconi, R. Evans, Mol. Phys. 1987, 60, 573-595.
36. B. C. Lippens, J. H. DeBoer, J. Catal. 1965, 4, 319-323.
37. Y. Takehara, K. Sumii, A. Tari, M. Yoshihara, M. Sumii, K. Haruma, G. Kajiyama, S. V. Wu, J. H. Walsh, Am. Physiol. Soc. 1996, 271, G799-804.